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ABSTRACT Nerve growth factor (NGF) mimics play an important role for therapies that target the receptor tyrosine kinase A
(trkA). The N-terminal fragment of the NGF (N-term@NGF) was previously demonstrated to be an important determinant for
afﬁnity and speciﬁcity in the binding to trkA. Here we use a variety of computational tools (contact surface analysis and free
energy predictions) to identify residues playing a key role for the binding to the receptor. Molecular dynamics simulations are
then used to investigate the stability of complexes between trkA and peptides mimicking N-term@NGF. Steered molecular
dynamics calculations are ﬁnally performed to investigate the process of detaching the peptide from the receptor. Three
disruptive events are observed, the ﬁrst involving the breaking of all intermolecular interactions except two salt bridges, which
break subsequently.
INTRODUCTION
Neurotrophins constitute a family of structurally related pro-
teins, which promote and regulate the survival of neurons in
the vertebrate nervous system (1–3). This family includes the
nerve growth factor (NGF) as well as the brain-derived neuro-
trophic factor, Neurotrophin-3 and Neurotrophin-4/5 (4).
Mature neurotrophins are homodimers that are derived
by proteolytic cleavage from precursor proteins (5). These
proteins bind with similar afﬁnity to the receptor p75NTR,
a member of the tumor-necrosis-factor receptor superfamily,
and selectively to the members of the receptor tyrosine
kinase (trk) family, namely trkA, trkB, and trkC, which are
involved in the activation of different intracellular signal
transduction cascades (6–9). Speciﬁcally, NGF binds with
the highest afﬁnity to trkA (10–12), which mediates the
survival-promoting and neurite-growth-promoting effects of
NGF during development (13–16).
Because of their crucial role for nervous system develop-
ment, neurotrophins may reduce neuronal degeneration in
neurodegenerative diseases, such as Alzheimer’s (17–24).
However, a major obstacle to the neurotrophin-based ther-
apies is their delivery: signiﬁcant doses of proteins must be
achieved in the target region to really counteract disease
processes and, simultaneously, this delivery must be ham-
pered in other regions to prevent side-effects (25–27). A
promising strategy involves the use of peptide mimics, i.e.,
molecules with either agonist or competitive antagonist ef-
fect and retaining the most essential elements of neurotrophic
action, which may be useful in the treatment of several
neurodegenerative diseases and nerve injuries (28–31). For
NGF, such peptides have been shown to exhibit neurotrophic
effects by binding to trkA (32–38).
The ligand/receptor interface involves two patches: one
comprises residues of NGF core region and loops of the
C-term of the ﬁfth extracellular domain of trkA (trkA-d5),
the other includes the N-terminal fragment of NGF (N-term@
NGF) and the ABED b-sheet of trkA-d5 (39,40) (Fig. 1 a).
The latter is known to determine the afﬁnity and speciﬁcity
of the NGF binding to trkA, as indicated by experimental
data (15,41–46) and further suggested by molecular dynam-
ics (MD) calculations (47).
Here we attempt at identifying a short peptide as a trkA-d5
high-afﬁnity mimic of the N-term@NGF. Our work is based
on the x-ray (39) and the MD (47) structures of the NGF/
trkA-d5 complex (Fig. 1 a). First, we identify NGF residues
exhibiting signiﬁcant contact surface, and thus nonpolar inter-
action, with the receptor; among those, we locate the residues
forming signiﬁcant electrostatic interaction and/or binding-
energy hot-spots, as deﬁned in Kortemme and Baker (48)
and Kortemme et al. (49). Based on this analysis, we con-
clude that residues from 4 to 13 (H4PIFHRGEFS13, ac-
cording to the pdb 1WWW numeration (39,50)), at the
N-term, may have high afﬁnity for trkA-d5.
Subsequently, under the assumption that the mode of
binding of the peptide is similar to that of the original pro-
tein, we investigate the conformational ﬂexibility of the ad-
duct formed by the H4PIFHRGEFS13 peptide with trkA-d5
using MD (Fig. 1 b). The stability of the ‘‘complementary’’
complex, i.e., the complex in which the same peptide is
removed from NGF, is also explored by MD (Fig. 1 d). Our
calculations conﬁrm that most residues belonging to the
4–13 peptide are important for trkA-d5 binding, His-8 and
Ser-13 being the only groups not stabilizing the complex.
Thus, we modify the peptide mimic by deleting Ser-13 and
mutating His-8 to Gly, which ensures a larger ﬂexibility of
the peptide. MD simulations carried out on the resulting
peptide (H4PIFGRGEF12) suggest that the latter, despite its
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shorter length, forms an additional salt bridge with the
receptor, besides those originally formed by Arg-9 and Glu-
11. Thus, we identify this peptide as a high-afﬁnity mimic of
the N-term@NGF. As a ﬁnal step, we investigate the binding
process by steered MD (51–59), and the aforementioned salt
bridges turn out to be the most persistent interactions be-
tween the ligand and the receptor.
METHODS
All calculations discussed here are based on the last snapshot of our previous
MD simulation of the NGF/trkA-d5 complex (see Supplementary Material)
(47). Calculations based on the x-ray structure (39) yield very similar results,
which are not commented on here (Table 2).
We focus on structural (item 1, below) and energetic (items 2 and 3,
below) features associated with the binding of chain Y of trkA-d5 to NGF
homodimer in complex with the other receptor chain X:
trkA-d5ðYÞ1NGF  trkA-d5ðXÞ/trkA-d5ðYÞ  NGF
 trkA-d5ðXÞ
1. We calculate the difference of the solvent-accessible surfaces of NGF
in the presence and in the absence of trkA-d5(Y), here called contact-
surface (CS). CS provides a rough estimate of the nonpolar contribution
to the binding free energy (60). We use the center-probe area deﬁnition
(61) and set the solvent probe radius to 0.14 nm (62,63). The residues
FIGURE 1 (a) Ca trace of the NGF/trkA-d5 complex as
obtained by the MD simulation of Settanni et al. (47). Each
of the two NGF identical subunits (black) binds to a trkA-
d5 subunit (gray). The trace is thicker for the residues
involved in NGF/trkA-d5 molecular recognition. The trkA-
d5/N-term@NGF regions are further marked with two
ellipses. (b) Ca trace of the complex formed by trkA-d5
and H4PIFHRGEFS13 (c1). A second peptide in c2 differs
from that in c1 for the replacement of His-8 with Gly and
the removal of Ser-13. Both c1 and c2 are investigated here
by MD simulations. (c) TrkA-d5/peptide interactions in c1
and c2. The van der Waals and H-bond interactions are
depicted as continuous and dashed lines, respectively.
His-4 is accommodated in a receptor’s pocket lined by His-
291, Pro-302, and His-343; at the bottom, His-4 hydrogen
bonds with Phe-303 and Gly-344. The Pro-5 side chain
interacts with His-343 and Leu-333. Ile-6 is positioned in
another receptor’s pocket lined by Val-294, Met-296, and
Leu-333; at the bottom, Ile-6 side chain forms van der
Waals interactions with the receptor surface-exposed
disulﬁde region between Cys-345 and Cys-300. Phe-7
interacts with Val-294, Arg-9 with Glu-334, Gly-10 with
Met-296, Glu-11 with Arg-347, Phe-12 with Met-296, and
Ser-13 with Met-296. His-8 does not interact with trkA-d5.
Glu-339, which is boxed, interacts with Arg-9 only in c2.
(d) Ca trace of the trkA-d5/NGF complex without
S2SHPIFHRGEFS13 residues (c3). Also, this complex
undergoes MD simulation. The initial structure (thick
trace) is compared with the last c3 MD snapshot (thin
trace) (87).
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providing the largest CS in the NGF N-term region turn out to be located
between His-4 and Ser-13 (sequence H4PIFHRGEFS13).
2. The Poisson-Boltzmann equation (64) is applied to calculate the elec-
trostatic contribution to the free energy of binding DGEB (65):
DG
E
B ¼ GEtrkA-d5ðXÞNGFtrkA-d5ðXÞ  GENGFtrkA-d5ðXÞ  GEtrkA-d5ðXÞ
Each molecule is assumed to adopt the same conformation in the
complex and in the isolated form. Then, the change of DGEB upon




B ¼ DGEBðR/AlaÞ  DGEBðWTÞ
The structures of the mutated protein are obtained by deleting all the
side-chain atoms of residue R except the Cb, which is saturated.
Then, the structures undergo an energy minimization, using
the standard pairwise generalized Born/surface area model of
solvation (66,67), as implemented in the AMBER7 program
(68). We use the AMBER99 force ﬁeld (69,70), assuming
100 mM monovalent ionic concentration, protein dielectric con-
stant ein ¼ 2, and solvent dielectric constant ewat ¼ 78.5.
DGEB is calculated using the APBS program (71) under the
following conditions: the nonlinear Poisson-Boltzmann equation
is solved; the temperature is set to 300 K; a 100 mM monovalent
ion concentration is assumed; the Connolly molecular surface
deﬁnition (72) is used; a two-runs focusing procedure is applied.
Initially we run the APBS program with boundary conditions
deﬁned using a Debye-Hu¨ckel model for multiple charged
spheres, along with a grid spacing of 0.067 nm. Then, we run the
program with boundary conditions derived from the ﬁrst run,
with grid spacing as small as 0.047 nm. Test-calculation with a
ﬁner grid spacing, i.e., 0.045 nm, shows that the calculated free
energies differ by ;0.2 kJ/mol (’0.1 kT).
3. We calculate which NGF residues at the NGF/trkA-d5(Y) interface
contribute signiﬁcantly to the complex stability using Baker’s com-
putational alanine scanning procedure (48,49). The predictor locates the
residues at the interface, which may signiﬁcantly destabilize the com-
plex when mutated to alanine, estimating both the van der Waals and the
electrostatic contributions to the free energy of binding. Binding energy
hot-spots are deﬁned as residues whose DDGhsB $ 2 kT . The prediction
is performed on the entire NGF/trkA-d5 and on the N-term@NGF
mimic/trkA-d5 complexes.
Molecular dynamics calculations
We perform MD simulations on:
1. The complex formed by trkA-d5 and the N-term@NGF derived peptide
H4PIFHRGEFS13 (c1, Fig. 1 b). His-4 and Ser-13 are terminated by
acetyl and N-methyl groups, respectively.
2. The complex formed by trkA-d5 and the peptide of sequence
H4PIFGRGEF12 (c2).
3. The trkA-d5/NGF complex without such peptide, along with Ser-2 and
Ser-3 (c3, Fig. 1 d).
c1, c2, and c3 are solvated in rectangular water boxes (Table 1). The same
computational protocol is used for c1, c2, and c3. We use the AMBER99
force ﬁeld (69,70) and TIP3P (73) for the biomolecules and water,
respectively. Calculations are performed using the GROMACS program
(74). Periodic boundary conditions are applied. Particle mesh Ewald is used
to evaluate long-range electrostatics (75–77). A cutoff of 1 nm is used for the
real part of the electrostatics and for the van der Waals interactions.
Constraints are applied to the bonds using the LINCS algorithm (78). The
integration time step is set to 1.5 fs.
Equilibration runs are carried out using the Berendsen thermostat and
barostat (79). The solvent undergoes;50 ps of MD simulations keeping the
protein atoms ﬁxed to achieve the correct solvent density. Subsequently, the
systems are energy-minimized and gradually heated by eight MD runs with
increasing temperature (22.5 ps each, from 0 to 10, 30, 70, 100, 150, 200,
250, and 300 K). The 5.7 ns of MD simulations in the NPT ensemble (T ¼
300 K and P¼ 1 atm) are then performed using the Nose´-Hoover thermostat
(80,81) and the Parrinello-Rahman procedure (82,83); the pressure coupling
is isotropic in all directions.
Rootmean square deviations (RMSD) are calculated for Ca atoms using the
x-ray structure (39) as the reference conformation. RMSD plots for c1 and c2
ﬂuctuate at ;0.15 nm within the ﬁrst 0.6 ns, which are discarded; on the
contrary, the sameplot calculated for c3displays increasingRMSD(Fig. 2).The
maximaldistanceallowed for the existenceof anH-bondbetweenhydrogenand
acceptor atom is 0.25 nm, while the maximal supplement of the donor-
hydrogen-acceptor angle is 60, 0 corresponding to the extendedconformation.
Two oppositely charged residues are assumed to form a salt-bridge interaction
when at least one H-bond can be detected between their side chains.
Steered molecular dynamics
Three nanoseconds of steered molecular dynamics (SMD) (51–59) are
carried out in the NPT ensemble with the same setup, based on the c2 MD
last snapshot, except that the peptide is harmonically restrained (force
constant is 1000 kJ/(mol 3 nm2) (51,54,56,59)). The restraint is initially
applied at the peptide mass center and moves away from the receptor mass
center with a velocity of 0.5 nm/ns. An additional 4 ns long SMD simulation
is performed with the same setup but at 0.25 nm/ns restraint-point velocity.
Then, 5.4 ns of MD in the NPT ensemble, with the same setup as above, is
performed. Finally, the unbound peptide is immersed in a smaller water box
(‘‘unbound peptide’’ in Table 1) and 25 ns of MD simulation in the NPT
ensemble is performed.
RESULTS AND DISCUSSION
A calculation of the contact surface (CS) (61) between trkA-
d5 and NGF suggests that the NGF residues from His-4 to
Ser-13 form signiﬁcant contacts with the receptor (CS. 0.20
nm2), except His-8 and Gly-10. In particular, His-4 and Ile-6
form the most extensive contacts with the receptor, being
accommodated in speciﬁc pockets (Fig. 1 c and Table 2).
TABLE 1 Selected features of the three complexes (c1, c2, and c3; see also Fig. 1, b and d) and of the unbound peptide systems
investigated in this work
Box edges (nm)
Complex name Amino acids N-methyl groups Acetyl groups Water molecules Sodium ions x y z
c1 111 2 2 9689 4 7.6 7.2 5.8
c2 110 2 2 9538 4 7.3 7.2 6.3
c3 407 4 4 24165 2 12.8 9.5 6.7
Unbound peptide 9 1 1 2987 0 5.1 4.3 4.2
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Being based on a solvent-accessible surfaces calculation, CS-
based methods provide a rough estimate of the nonpolar
interaction (60) and thus of the residues which are responsible
for the most relevant hydrophobic contributions to the overall
free energy of binding. Only a few other NGF residues have
such signiﬁcant CS: Ser-19, Trp-21, Tyr-52, Phe-54, Arg-59,
Ile-145, Lys-146, Gly-147, Thr-197, His-198, Arg-217,
and Val-225. This indicates again the relevance of the
N-term@NGF for ligand/receptor interaction (15,41–47).
To dissect the most important electrostatic interactions be-
tween N-term@NGF and trkA-d5, we perform electrostatic
alanine scanning calculations (65). We calculate the elec-
trostatic free energy of receptor binding to the ligand in which
the residue R is mutated to Ala and then we subtract the cor-
responding free energy calculated for the native peptide. The
larger the resulting DDGEB, the greater the electrostatic
contribution of residue R side chain to the binding free en-
ergy. Here we distinguish H-bonds from salt bridges, which
are characterized by a larger desolvation penalty upon for-
mation and by a much stronger electrostatic attraction, in-
volving two oppositely charged groups (84). His-4, Arg-9,
and Glu-11 turn out to provide the most negative electrostatic
free energies, presumably because of H-bond and salt-bridge
interactions with the receptor (namely, with residues Phe-303,
Gly-344, Glu-334, and Arg-347; see Fig. 1 c and Table 2). A
similar picture is obtained by applying the Baker’s binding-
energy hot-spot predictor (48,49): within the N-term region,
His-4, Ile-6, Arg-9, Glu-11, and Phe-12 signiﬁcantly con-
tribute to the complex stability ðDDGhsB $ 2 kT, Table 2).
We conclude that NGF residues from His-4 to Ser-13 have
good afﬁnity for trkA-d5, with the exception of His-8. Thus,
we may expect that the peptide which has the same sequence
(H4PIFHRGEFS13) might have good afﬁnity for the recep-
tor. To investigate the stability of this peptide with trkA-d5
(c1, Fig. 1 b), we perform an MD simulation along with a
complementary system, which comprises both receptors
trkA-d5 and the whole NGF without the N-terms (c3, Fig.
1 d). As for the peptide, we assume that its mode of binding
is similar to that of full-length NGF.
The results of the simulation of c1 are summarized in Fig.
2 and in Table 3. The RMSD ﬂuctuates around a relatively
small value (0.15 nm, Fig. 2) and the peptide/receptor con-
tacts are maintained as in the full complex, with the notable
FIGURE 2 RMSDs (black line) and CS between ligand and the receptor
(gray line) calculated for the three complexes investigated here by MD. The
inset shows the RMSDs of NGF and trkA-d5 chains X and Y in c3
(continuous black line, dashed black line, and continuous gray line,
respectively).







1WWW f.c. c1 c2 1WWW f.c. c1 c2
His-4 1.03 1.06 1.00 1.19 2.99 5.40 4.60 5.18 3.44
Pro-5 0.47 0.51 0.57 0.36 1.47 – – – –
Ile-6 0.79 0.83 0.95 0.72 0.55 2.10 2.06 2.95 2.47
Phe-7 0.39 0.49 0.54 0.25 0.84 1.27 – 1.44 1.39
His-8(Gly) 0 0 0 0 0 – 0.49 – –
Arg-9 0.44 0.57 0.53 1.06 2.52 0.29 2.11 2.06 2.99
Gly-10 0.02 0.08 0.04 0.07 – – – – –
Glu-11 0.65 0.68 0.90 0.83 6.33 0.69 2.50 1.83 2.82
Phe-12 0.30 0.29 0.45 0.38 0.22 0.70 4.18 0.70 1.93
Ser-13 0.34 0.39 0.10 * 2.13 0.35 0.35 0.22 *
Contact surface (CS) (61), electrostatic alanine scanning calculations (DDGEBÞ (65), and binding energy hot-spot predictions ðDDGhsB Þ (48,49) are reported for
NGF residues from His-4 to Ser-13. The NGF/trkA-d5 full-complex (f.c.) is the last MD snapshot of the previously performed simulation (47) and the c1 and
c2 conformations are those after 5.7 ns of MD.
*In c2, Ser-13 is absent.
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exception of Ser-13: this residue is much more solvated here
than in the full complex (Tables 2 and 3) and it is not in-
teracting with trkA-d5 as in the full complex. Our calcula-
tions further conﬁrm that His-8 does not form interactions
with the receptor. This suggests that His-8 can be substituted
by a simpler residue like Gly or Ala. Since Gly allows for a
higher ﬂexibility of the peptide, which in turn might assist
trkA-d5 binding, we substitute here His-8 with Gly.
We probe then the stability of the peptide in which His-8 is
mutated to Gly and Ser-13 is absent (H4PIFGRGEF12, c2).
This peptide is expected to interact with the receptor as
strongly as H4PIFHRGEFS13, being one amino acid shorter.
The peptide interacts with trkA-d5 as in c1, except Arg-
9@NGF: the salt bridge formed by this residue with Glu-
334@trkA is almost always broken and the H-bond formed
with the backbone of Glu-334@trkA is strengthened.
Moreover, a new salt bridge, not present in c1, is observed
between Arg-9@NGF and Glu-339@trkA but only in
40% of the trajectory (Fig. 1 c and Table 3): this interaction
is therefore weaker than the salt bridge between Arg-
9@NGF and Glu-334@trkA in c1 (84%). However,
it is compensated by the formation of an H-bond between
Arg-9@NGF and Glu-334@trkA backbone (Table 3). Both
terminal residues are forming signiﬁcant interaction with the
receptor, unlike in c1. The complex is stable, with the RMSD
ﬂuctuating at ;0.15 nm (Fig. 2). The Baker’s binding-
energy hot-spots predictor (48,49), applied to the last c2
snapshot, suggests that all of the peptide residues, except
Pro-5, Gly-8, and Gly10, are signiﬁcantly contributing to the
complex stability (Table 2). We conclude that the larger
conformational ﬂexibility of the peptide caused by the His-8
to Gly mutation might assist the formation of a new salt
bridge interaction.
Very different results are obtained for the complex be-
tween trkA-d5 and the NGF lacking the N-term segments (c3
in Fig. 1 d). In this case, although we start from the bound
conformation of the full complex, the receptor slowly de-
taches from the N-terms deleted neurotrophin, as evinced
from the RMSD that grows during the simulation and the CS
between NGF homodimer and the receptors that decreases,
indicating an increase of the solvation of the different
subunits during the dynamics (Fig. 1 d and Fig. 2). The cal-
culation is stopped after 5.7 ns of MD, as the previously de-
scribed simulations. Although the results strongly suggest
a dissociation of the complex, observing such an event re-
quires a timescale that is currently not covered by MD
simulations.
We conclude that the interactions of the peptide in c2 with
the receptor appear to be far stronger than those formed by
the rest of the neurotrophin.
Steered molecular dynamics
Steered molecular dynamics (SMD) is based on the ﬁnal MD
snapshot of c2 (Fig. 3 b). Although the investigation of the
entire molecular recognition process is beyond the domain of
applicability of molecular simulation methods, useful qual-
itative insights on the ligand/receptor binding process can be
obtained by steering the ligand away from the receptor and
observing the applied force proﬁle (51–59).
Here we apply such an approach to the case of c2, by
monitoring the external force and the distance between the
mass centers of ligand and receptor as a function of the sim-
ulated time (Fig. 3 a). Until 0.8 ns the distance is almost
constant, no ligand/receptor interactions are broken, and the
force grows linearly as fast as 1.12 pN/ps. Then, at ;1 ns,
the force is large enough to break almost simultaneously all
intermolecular interactions except the salt bridges formed by
Arg-9@NGF and Glu-11@NGF. The breaking of all these
interactions determines a sharp decrease of the force, an
increase of the receptor/peptide mass centers distance and of
the solvation of the NGF residues (Fig. 3 a). The force is now
much smaller and does not change on the disruption, at
;1.45 ns, of the salt bridge formed by Arg-9, which is
observed in c1 and in c2 to be the least stable among the two
peptide/receptor salt bridges (Table 3). In contrast, it
decreases suddenly on the rupture of the last interaction,
the salt bridge formed by Glu-11, at;2.15 ns (Fig. 3 a). The
TABLE 3 Ligand-receptor interactions in c1 and c2 complexes
NGF trkA-d5 c1 c2
H-bonds (%)
His-4 Ne Phe-303 O 87 99
His-4 Ne Gly-344 O 22 3
Arg-9 sc Glu-334 O 4 72
Salt bridges (%)
Arg-9 sc Glu-334 sc 84 1
Arg-9 sc Glu-339 sc 0 40
Glu-11 sc Arg-347 sc 100 100
Hydrophobic contacts (nm)
His-4 Phe-303 0.29 (0.02) 0.28 (0.01)
His-4 Gly-344 0.33 (0.04) 0.35 (0.03)
His-4 His-291 0.48 (0.13) 0.38 (0.04)
His-4 Pro-302 0.36 (0.02) 0.36 (0.02)
His-4 His-343 0.37 (0.03) 0.38 (0.03)
Pro-5 His-343 0.36 (0.02) 0.36 (0.02)
Pro-5 Leu-333 0.40 (0.03) 0.40 (0.04)
Ile-6 Leu-333 0.40 (0.05) 0.38 (0.03)
Ile-6 Cys-345 0.38 (0.03) 0.38 (0.03)
Ile-6 Cys-300 0.41 (0.04) 0.44 (0.04)
Ile-6 Met-296 0.35 (0.03) 0.41 (0.05)
Ile-6 Val-294 0.40 (0.04) 0.47 (0.05)
Phe-7 Val-294 0.43 (0.08) 0.41 (0.05)
Arg-9 Glu-334 0.29 (0.05) 0.33 (0.10)
Arg-9 Glu-339 1.14 (0.21) 0.45 (0.21)
Gly-10 Met-296 0.44 (0.06) 0.63 (0.10)
Glu-11 Arg-347 0.27 (0.01) 0.27 (0.01)
Phe-12 Met-296 0.34 (0.02) 0.37 (0.04)
Ser-13 Met-296 0.42 (0.09) *
H-bonds, salt bridges, and minimum distances between nonhydrogen atoms
of couples of interacting residues, as described in Fig. 1 c. The term sc
means side chain.
*In c2, Ser-13 is absent.
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hydration of the ligand increases at each of these disruptive
events (inset in Fig. 3 a). To check the reliability of our
results, a second SMD simulation is performed by applying
an external force that increases slower: a qualitatively similar
unbinding process is observed (Fig. 4).
After a total of 3 ns of SMD, the peptide is unbound from
the receptor and further 5.4 ns of MD are performed, without
applying external force to the peptide (Fig. 3 c). The mean
RMSD calculated for the receptor is 0.14 (0.02) nm and the
conformation of the unbound trkA-d5 is very similar to that
of the receptor bound to NGF (85); the mean RMSD for the
peptide is 0.30 (0.05) nm (Fig. 3 d).
By performing 25 ns of MD simulation of the peptide, we
observe that the peptide is folding into itself progressively:
the RMSD is 0.26 nm at 0 ns and 0.20 nm at 25 ns. Arg-9 and
Glu-11 do not form an intrapeptide salt bridge either here
or in the previous complexes; two intrapeptide H-bonds,
between Ile-6 N and His-4 Nd and between Phe-7 N and
His-4 O are maintained during the dynamics. The side chains
are oriented as in the bound peptide, with the exception of
Glu-11 side chain, that interacts with the backbone of the
peptide C-term part.
CONCLUDING REMARKS
Our simulations suggest that the ACEHPIFGRGEFNME
peptide may provide high afﬁnity to the trkA-d5 receptor,
as all the residues form interactions with the receptor except
the Gly-8 and Gly-10 residues; however, the latter provides
conformational ﬂexibility, allowing the peptide to form an
additional interaction with the receptor.
SMD calculations suggest that the strengths of the
contacts between the peptide and its target are similar, with
the exception of the salt bridges formed by Arg-9 and Glu-11
with trkA-d5 (Fig. 1 c). These interactions are the most per-
sistent in the SMD, possibly because of the large ﬂexibility
FIGURE 3 Steered molecular dynamics of c2 moving the restraint point with a velocity of 0.5 nm/ns. (a) Distance between the mass centers of trkA-d5 and
of the ACEHPIFGRGEFNME peptide (solid line) and force on the peptide (dashed line) plotted as a function of the simulation time. The peptide/receptor
interactions are broken after 1.1 ns of SMD, except the salt bridges formed by the peptide residues Arg-9 and Glu-11, which break down at;1.45 ns and;2.15 ns
of SMD, respectively. The inset shows the number of water oxygens within 0.45 nm of nonhydrogen atoms of the peptide residues, as a function of the
simulation time. (b,c) Structure of c2 at the beginning (b) and at the end (c) of the simulation: the Ca trace of the receptor is represented (green at 5.7 ns of MD,
red after 3 ns of SMD and further 5.4 ns of MD), along with the sticks representation of the peptide, colored by atom type. (d) Separated ﬁt of the peptide and of
the receptor structures in the initial (green) and the ﬁnal (red) conformations (87).
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and length of the side chains involved, which can rearrange
so as to maintain the electrostatic interactions despite the in-
crease of the peptide/receptor distance, with respect to all the
other residues at the interface.
The challenge is now to perform in vitro and in vivo ex-
periments which may quantify the actual efﬁcacy of this
peptide as an agonist or competitive antagonist (25,86).
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